{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-025817","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.623855+00:00","generated_at":"2026-05-15T15:09:10.891567+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CERo Therapeutics issues $750K convertible note to Keystone Capital with conversion price floor at $0.05","bullets":["Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.","Note bears 10% interest, matures August 6, 2027; conversion price is lesser of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.","Beneficial ownership limitation of 4.99%; company must file registration statement for resale of conversion shares.","Offered under Section 4(a)(2) and Rule 506(b) exemption; no public offering.","Maximum aggregate borrowing up to $1,000,000 under the note."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-025817","json":"https://secwatch.observer/filing/0001213900-26-025817.json","markdown":"https://secwatch.observer/filing/0001213900-26-025817.md","text":"https://secwatch.observer/filing/0001213900-26-025817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/ea0280905-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:09:10.891567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50dd6331f5e0f9b5b43fbc34b6c8db1986de03c7","claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate with Keystone Capital Partners, LLC at 10% per annum maturing August 6, 2027.","evidence_excerpt":"On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"August 6, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"dec6d57a5d4af89df6b1f2d7896d818bd5ce32f5","claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $750,000.","evidence_excerpt":"On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"Keystone Capital Partners, LLC"},{"label":"Consideration","value":"purchase price of $750,000"}],"fact_type":"equity_issuance"},{"claim_id":"dd698a7d3132bc338735127c2283fe682a049c05","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Convertible Promissory Note with Keystone Capital Partners, LLC valued at Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Value","value":"Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int"},{"label":"Effective","value":"2026-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}